Research ArticleCLINICAL INVESTIGATIONS
68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT
Michael Gabriel, Clemens Decristoforo, Dorota Kendler, Georg Dobrozemsky, Dirk Heute, Christian Uprimny, Peter Kovacs, Elisabeth Von Guggenberg, Reto Bale and Irene J. Virgolini
Journal of Nuclear Medicine April 2007, 48 (4) 508-518; DOI: https://doi.org/10.2967/jnumed.106.035667
Michael Gabriel
Clemens Decristoforo
Dorota Kendler
Georg Dobrozemsky
Dirk Heute
Christian Uprimny
Peter Kovacs
Elisabeth Von Guggenberg
Reto Bale
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT
Michael Gabriel, Clemens Decristoforo, Dorota Kendler, Georg Dobrozemsky, Dirk Heute, Christian Uprimny, Peter Kovacs, Elisabeth Von Guggenberg, Reto Bale, Irene J. Virgolini
Journal of Nuclear Medicine Apr 2007, 48 (4) 508-518; DOI: 10.2967/jnumed.106.035667
68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT
Michael Gabriel, Clemens Decristoforo, Dorota Kendler, Georg Dobrozemsky, Dirk Heute, Christian Uprimny, Peter Kovacs, Elisabeth Von Guggenberg, Reto Bale, Irene J. Virgolini
Journal of Nuclear Medicine Apr 2007, 48 (4) 508-518; DOI: 10.2967/jnumed.106.035667
Related Articles
Cited By...
- SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors
- Importance of PET with 68Ga-Labeled Somatostatin Analogs (perspective on "68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT" J Nucl Med. 2007;48:508-518)
- Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy
- Safety, tolerability and clinical implementation of 'ready-to-use 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
- Improving Contrast and Detectability: Imaging with [55Co]Co-DOTATATE in Comparison with [64Cu]Cu-DOTATATE and [68Ga]Ga-DOTATATE
- 111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden
- Multimodality imaging in carcinoid heart disease
- Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy
- CMKLR1-targeting peptide tracers for PET/MR imaging of breast cancer
- Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study
- Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study
- Current Concepts in 68Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies
- 68Ga-DOTATOC Imaging of Neuroendocrine Tumors: A Systematic Review and Metaanalysis
- Somatostatin Receptor 2-Targeting Compounds
- Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor
- The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis
- Parametric Net Influx Rate Images of 68Ga-DOTATOC and 68Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast
- MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with 68Ga-DOTATATE and 18F-FDG and Multimodality Anatomic Imaging in Metastatic Neuroendocrine Tumors of Unknown Primary in a PRRT Workup Setting
- Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors
- 68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients
- Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors
- 68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG-Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin
- A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management
- Clinical Translation of a Click-Labeled 18F-Octreotate Radioligand for Imaging Neuroendocrine Tumors
- Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors
- Potential value of EUS in pancreatic surveillance of VHL patients
- Evaluation of the Efficacy of Targeted Imaging Agents
- Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites
- Significance of a Single-Time-Point Somatostatin Receptor SPECT/Multiphase CT Protocol in the Diagnostic Work-up of Gastroenteropancreatic Neuroendocrine Neoplasms
- Appendiceal neuroendocrine neoplasms: diagnosis and management
- Prognostic Value of 68Ga-DOTANOC PET/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas
- 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients
- Increased 68Ga-DOTATATE Uptake in PET Imaging Discriminates Meningioma and Tumor-Free Tissue
- Can Complementary 68Ga-DOTATATE and 18F-FDG PET/CT Establish the Missing Link Between Histopathology and Therapeutic Approach in Gastroenteropancreatic Neuroendocrine Tumors?
- 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-Octreotide SPECT/CT, and Whole-Body MR Imaging in Detection of Neuroendocrine Tumors: A Prospective Trial
- Preclinical Evaluation of a High-Affinity 18F-Trifluoroborate Octreotate Derivative for Somatostatin Receptor Imaging
- Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art
- PET/MR in Oncology: Non-18F-FDG Tracers for Routine Applications
- 18F-Fluorodihydroxyphenylalanine PET/CT in Patients with Neuroendocrine Tumors of Unknown Origin: Relation to Tumor Origin and Differentiation
- Promises of Cyclotron-Produced 44Sc as a Diagnostic Match for Trivalent {beta}--Emitters: In Vitro and In Vivo Study of a 44Sc-DOTA-Folate Conjugate
- Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors After Treatment with [177Lu-DOTA0,Tyr3]Octreotate
- Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors
- The Role of 68Ga-DOTATATE PET/CT in Suspected Neuroendocrine Tumors
- Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications
- Tumor Response Assessment to Treatment with [177Lu-DOTA0,Tyr3]Octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors: Differential Response of Bone Versus Soft-Tissue Lesions
- Clinical PET of Neuroendocrine Tumors Using 64Cu-DOTATATE: First-in-Humans Study
- A Man with Abdominal Pain: Enough Evidence for Surgery?
- Nuclear medicine imaging of neuroendocrine tumours
- Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
- The SNM Practice Guideline for Somatostatin Receptor Scintigraphy 2.0
- Radiopeptide Imaging and Therapy in Europe
- 68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors
- Novel SDHD Gene Mutation (H102R) in a Patient With Metastatic Cervical Paraganglioma Effectively Treated by Peptide Receptor Radionuclide Therapy
- Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors
- Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours
- 177Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma
- Somatostatin Receptors as Targets for Nuclear Medicine Imaging and Radionuclide Treatment
- Incidence of Increased 68Ga-DOTANOC Uptake in the Pancreatic Head in a Large Series of Extrapancreatic NET Patients Studied with Sequential PET/CT
- 68Ga-DOTATOC PET/CT of Neuroendocrine Tumors: Spotlight on the CT Phases of a Triple-Phase Protocol
- Expression of somatostatin receptors, dopamine D2 receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas
- Diagnostics of Neuroendocrine Tumours
- Exendin-4-Based Radiopharmaceuticals for Glucagonlike Peptide-1 Receptor PET/CT and SPECT/CT
- The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy
- 68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors
- Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
- Features of Carcinoid Heart Disease Identified by 2- and 3-Dimensional Echocardiography and Cardiac MRI
- A Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in Pulmonary Neuroendocrine Tumors
- 68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor-Mediated Radionuclide Therapy
- Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy
- The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors
- 99mTc-HYNIC-TOC Scintigraphy Is Superior to 131I-MIBG Imaging in the Evaluation of Extraadrenal Pheochromocytoma
- New Technologies for Human Cancer Imaging
- Tumor Receptor Imaging
- Utility of Radiolabeled Somatostatin Receptor Analogues for Staging/Restaging and Treatment of Somatostatin Receptor-Positive Pediatric Tumors
- Somatostatin Receptor Imaging in Patients with Neuroendocrine Tumors: Not Only SPECT?